An observational study in Acute Myeloid Leukemia (AML) and Ewing Sarcoma, sponsored by asmaa salama ibrahim. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by asmaa salama ibrahim · Observational
Ewing's sarcoma is an uncommon yet vital malignancy of bone. It demonstrates a predilection for the pediatric and young adult population. Chemotherapy is considered an important treatment modality for Ewing's sarcoma. However, the development of therapy-related leukemia, especially acute myeloid leukemia following treatment, is attributed to the use of substances such as alkylating agents and topoisomerase inhibitors which are genotoxic. There is a very few studies elaborating on the incidence rates of such complications. So, our aim is to quantify the risk of developing acute myeloid leukemia in Ewing sarcoma patients and provide an updated evidence to the literature.
2,971 studies on the registry are indexed under Leukemia, Myeloid, Acute; 745 are open to participants now.
This study's enrollment of 2,631 is above the median of 120 across 317 observational studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →asmaa salama ibrahim is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with Ewing sarcoma between 2000 and 2021, followed up for more than 10 years after the initial diagnosis. Site record ICD-O-3/WHO 2008 restricted to bone and soft tissue; and histological type ICD-O-3 specified as Ewing sarcoma (9364)
Exclusion Criteria:
The standardized incidence ratio and excess risk of developing acute myeloid leukemia in Ewing's sarcoma patients
The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and calculated the excess absolute risk for acute myeloid leukemia in Ewing's sarcoma patients.
Time frame: from Jan, 2000 till Dec, 2021
The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients across different racial groups
Time frame: from Jan, 2000 till Dec, 2021
The standardized incidence ratio and excess risk of second primary malignancies in Ewing's sarcoma patients between different stages
Time frame: from Jan, 2000 till Dec, 2021
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
asmaa salama ibrahim